AVLN drops 8.1% as Morgan Stanley cuts target to $53
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
Avalyn Pharma (NASDAQ:AVLN) shares dropped 8.1% after Morgan Stanley lowered its price target from $57 to $53, while maintaining an overweight rating. The company also reported a quarterly loss of $0.67 per share, missing estimates. Despite the downgrade, the consensus among analysts remains a "Moderate Buy" with an average price target of $59.20.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.